6 Papers
177 Citations
Paul Ling is an academic researcher from Uniformed Services University of the Health Sciences. The author has contributed to research in topics: Virus & Varicella zoster virus. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).
TL;DR: Three sets of data imply that the VZV strain Oka, which has been used to produce a live attenuated virus vaccine, accumulates low levels of gpV polypeptides relative to wild-type strains.
66
Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
Philip W. Lowry,Suzanne M. Solem,Brandi N. Watson,Celine M. Koropchak,Helen M. Thackray,Paul R. Kinchington,William T. Ruyechan,Paul Ling,John Hay,Ann M. Arvin +9 more
TL;DR: Variability in the capacity of herpesviral glycoproteins to elicit cell-mediated immunity in vivo is suggested in guinea-pigs and means that this major tegument protein of VZV could be a useful component for vaccine development.
42
Transcription from varicella-zoster virus gene 67 (glycoprotein IV).
TL;DR: Three transcripts map to the varicella-zoster virus (VZV) open reading frame (ORF) 67, which encodes glycoprotein IV (gpIV), confirming that VZV appears able to use unusual TATA box motifs.
37
A detailed analysis of transcripts mapping to varicella zoster virus gene 14 (glycoprotein V).
TL;DR: Strain Scott synthesizes about 20-fold more gpV-specific transcripts than a strain of the Oka vaccine virus, reflecting the amounts of gpV polypeptide accumulating in both strains; this implies that the defect in Oka gpVpolypeptides production is at the level of transcription.
23
A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus.
TL;DR: The increasing age of the general population in the United States is likely to lead to an increase in cases of recrudescent zoster with attendant morbidity, and a live attenuated VZV vaccine has been used extensively in Japan and is completing clinical trials in theUnited States.
21